.Pharmacolibrary.Drugs.ATC.R.R03BB54

Information

Tiotropium bromide, when used in combination with other bronchodilator agents, is a long-acting muscarinic antagonist (LAMA) used primarily for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. It acts by relaxing airway smooth muscle and improving airflow. The combination products are approved and widely used today for the long-term management of airway obstruction.

Pharmacokinetics

Estimated pharmacokinetic parameters for tiotropium bromide in combination products, as no specific published studies are available for pharmacokinetic modeling of the combination. The parameters are based on known single-agent tiotropium data in adult, healthy and COPD populations, assumed to be similar in the fixed-combination inhaled products.

References

1. Deeks, ED (2015). Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs 75(6) 665–673. DOI:10.1007/s40265-015-0371-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25773742

2. Wang, Z, et al., & Luo, Z (2020). Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD. Pulmonary pharmacology & therapeutics 63 101944–None. DOI:10.1016/j.pupt.2020.101944 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32916296

3. Liou, JT, et al., & Wang, MT (2018). Risk of Severe Cardiovascular Events From Add-On Tiotropium in Chronic Obstructive Pulmonary Disease. Mayo Clinic proceedings 93(10) 1462–1473. DOI:10.1016/j.mayocp.2018.05.030 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30104044

Revisions

• 06/2025 initial generated model